COMMUNIQUÉS West-GlobeNewswire

SlimTide Examined: 2026 Consumer-Focused Analysis of Ingredients, Claims, and Label Transparency
21/05/2026
Gut Microbiome Support Formula with Chicory Inulin, Resistant Starch, and Akkermansia Muciniphila Explained for Consumer Research Miami, FL, May 21, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by [...]
Biodesix to Participate in Upcoming Investor Conferences
21/05/2026
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming [...]
Vitacore Announces World-First Custom-Fit CPAP Mask Following Health Canada MDL Approval
21/05/2026
FormFit™ is the world’s first end-to-end custom-fit medical grade silicone CPAP mask, creating a precision fit for each individual face. VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- Vitacore, a deep [...]
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
21/05/2026
, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4 th , 2026 AUSTIN, Texas, May 21 th , [...]
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
21/05/2026
SHANGHAI, May 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
21/05/2026
- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company [...]
Hemab Therapeutics Reports First Quarter 2026 Financial Results
21/05/2026
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE, Mass. and [...]
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
21/05/2026
WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies [...]
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
21/05/2026
A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTA VIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than those who [...]
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
21/05/2026
Cardiovascular and Respiratory medicines to be supplied in Malaysia and the Philippines Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, [...]
Concept Life Sciences Partners with OpenBench to Deliver Success-Based Drug Discovery Services for Early-Stage Biotech
21/05/2026
CHAPEL-EN-LE-FRITH, United Kingdom and SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Concept Life Sciences, a leading global contract research organization (CRO) with expertise in integrated drug discovery and [...]
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
21/05/2026
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based [...]
BioPorto announces Interim Result for the First Quarter of 2026
21/05/2026
May 21, 2026 Announcement no. 11 BioPorto announces Interim Result for the First Quarter of 2026 Copenhagen, Denmark, May 21, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), [...]
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
21/05/2026
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa ( Pa ) Secondary objectives met with no immunogenicity observed, [...]
Nanobiotix annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
21/05/2026
PARIS et CAMBRIDGE, Mass., 21 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]
Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
21/05/2026
ORION CORPORATION PRESS RELEASE 21 MAY 2026 at 10:30 EEST Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM - 212 at the 2026 ASCO® Annual Meeting First clinical data from [...]
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
21/05/2026
Pluvicto ® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali ® NATALEE oral presentation to report prognostic and [...]
First quarter 2026 update: starting the year on track, with product innovation progress
21/05/2026
Louvain-la-Neuve, Belgium, 21 May 2026 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, shares its business update for the first quarter of 2026. Group Overview Solid commercial [...]
Déclaration Intermédiaire Premier Trimestre 2026: un début d’année sur la bonne voie, avec des avancées en matière d’innovation produits
21/05/2026
Louvain-la-Neuve, Belgique, le 21 mai 2026 - IBA (Ion Beam Applications SA), le leader mondial des technologies d’accélération de particules, publie aujourd'hui la revue de ses activités pour le premier trimestre 2026. [...]

Pages